Amgen says Lumakras plus immunotherapy for lung cancer needs further study

 A small study of Amgen Inc's Lumakras drug combined with immunotherapy found it helped 29% of advanced lung cancer patients, but liver toxicity was high and further study is needed, the company said ahead of the data presentation on Sunday at the World Conference on Lung Cancer in Vienna.

https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-says-lumakras-plus-immunotherapy-lung-cancer-needs-further-study-2022-08-07/